Stephanie Danskin's Contact Details

Stephanie Danskin's Company Details

KeraFAST

Boston, Massachusetts, US • 20 - 49 Employees
BioTech/Drugs

At Kerafast, our mission is to make unique laboratory-made research tools easily accessible to the global scientific community. Our portfolio includes cell lines, antibodies, small molecules, dyes and more, many of which are not available elsewhere. Since our founding in 2011, researchers from more than 170 institutions worldwide have made their innovative reagents available through our online platform, where the materials can be quickly accessed without needing to go through the traditional Material Transfer Agreement process. We handle all selling and shipping logistics for the providing laboratory, as well as return generous royalty payments from every sale. We therefore help providing labs save time and resources, while generating extra funding for further research. Procuring scientists can more easily discover and access unique reagents that are often unavailable elsewhere, while also funding the work of other researchers. This creates a global community of scientists contributing and accessing Reagents for the Greater Good to accelerate their own research as well as scientific progress overall. In 2018, Kerafast merged with Absolute Antibody, a UK-based company with a vision to make recombinant antibody technology available to all researchers. In 2022, we became part of Absolute Biotech, a new company that unites multiple life science brands into one organization specializing in antibody reagents and services. Learn more at absolutebiotech.com.